Drug intelligence / Profile preview

amoxicillin + amoxicillin + clavulanate + cefadroxil + cefpodoxime + cefalexin + ciprofloxacin + delafloxacin + doxycycline + levofloxacin + linezolid

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination of **eleven antibiotics**, all commonly used to treat a wide variety of bacterial infections. The agents included span multiple drug classes: - **amoxicillin**: a penicillin antibiotic that inhibits bacterial cell wall synthesis. - **clavulanate**: a beta-lactamase inhibitor that protects beta-lactam antibiotics from enzymatic degradation, enhancing their spectrum. - **cefadroxil**, **cefpodoxime**, **cefalexin**: cephalosporins (first and third generation) that inhibit bacterial cell wall synthesis. - **ciprofloxacin**, **delafloxacin**, **levofloxacin**: fluoroquinolones that inhibit bacterial DNA gyrase and topoisomerase IV. - **doxycycline**: a tetracycline antibiotic that inhibits protein synthesis by binding the 30S ribosomal subunit. - **linezolid**: an oxazolidinone that inhibits the initiation of bacterial protein synthesis by binding to the 50S ribosomal subunit. This combination would confer an extremely broad antibacterial spectrum, including coverage against many Gram-positive and Gram-negative organisms, and both typical and atypical bacteria. Such an extensive combination is not a standard or recognized pharmaceutical product, but a theoretical combination of many antibiotics from various classes.

02

Targets

Bacterial RibosomeBacterial 50S ribosomal subunitClass A BL (Class A beta-lactamase)DNA gyrasePBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on amoxicillin + amoxicillin + clavulanate + cefadroxil + cefpodoxime + cefalexin + ciprofloxacin + delafloxacin + doxycycline + levofloxacin + linezolid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + amoxicillin + clavulanate + cefadroxil + cefpodoxime + cefalexin + ciprofloxacin + delafloxacin + doxycycline + levofloxacin + linezolid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call